ECM
GNMK

Endurant Capital Management’s GenMark Diagnostics, Inc GNMK Stock Holding History

Endurant Capital Management’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-59,070
Closed -$535K – 99
2015
Q2 		$535K Buy
+59,070
New +$596K 0.16% 84

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Endurant Capital Management's GNMK Position: Q3 2015 in Review

Endurant Capital Management sold out of GenMark Diagnostics, Inc (GNMK) in Q3 2015, closing a stake of 59,070 shares — an estimated $535K sold.

Endurant Capital Management first reported a position in GNMK in Q2 2015 and held it in 1 quarter. The position peaked at $535K in Q2 2015. 88 funds tracked by Wall St. Rank hold GNMK as of Q3 2015.

  • Endurant Capital Management reported no remaining GenMark Diagnostics, Inc position as of Q3 2015 after selling out during the quarter.
  • Endurant Capital Management sold 59,070 GenMark Diagnostics, Inc shares in Q3 2015, an estimated $535K.
  • Endurant Capital Management first reported a position in GenMark Diagnostics, Inc in Q2 2015 and held it in 1 quarter.
  • Endurant Capital Management's GenMark Diagnostics, Inc position peaked at $535K in Q2 2015.
  • 88 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q3 2015.

Based on Endurant Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.